...
首页> 外文期刊>Asian Pacific Journal of Cancer Prevention >The High Expressed Serum Soluble Neural Cell Adhesion Molecule, a High Risk Factor Indicating Hepatic Encephalopathy in Hepatocelular Carcinoma Patients
【24h】

The High Expressed Serum Soluble Neural Cell Adhesion Molecule, a High Risk Factor Indicating Hepatic Encephalopathy in Hepatocelular Carcinoma Patients

机译:高表达的血清可溶性神经细胞粘附分子,是肝癌患者肝性脑病的高危因素

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Objective: To investigate whether the expression of serum soluble neural cell adhesion molecule (sNCAM)is associated with hepatic encephalopathy (HE) in hepatocelular carcinoma (HCC) patients. Materials andMethods: The Oncomine Cancer Microarray database was used to determine the clinical relevance of NCAMexpression in different kinds of human cancers. Sera from 75 HCC cases enrolled in this study were assessed forexpression of sNCAM by enzyme linked immunosorbent assay (ELISA). Results: Dependent on the OncomineCancer Microarray database analysis, NCAM was down regulated in 10 different kinds of cancer, like bladdercancer, brain and central nervous system cancer, while up-regulated in lung cancer, uterine corpus leiomyomaand sarcoma, compared to normal groups. Puzzlingly, NCAM expression demonstrated no significant differencebetween normal and HCC groups. However, we found by quantitative ELISA that the level of sNCAM in serafrom HCC patients with HE (347.4±151.9 ng/ml) was significantly more up-regulated than that in HCC patientswithout HE (260.3±104.2 ng/ml), the p-value being 0.008. sNCAM may be an important risk factor of HE inHCC patients, the correlation coefficients was 0.278 (P< 0.05) on rank correlation analysis. Conclusions: Thisstudy highlights that up-regulated level of serum sNCAM is associated with HE in HCC patients and suggeststhat the high expression can be used as an indicator.
机译:目的:探讨肝细胞癌(HCC)患者血清可溶性神经细胞粘附分子(sNCAM)的表达是否与肝性脑病(HE)有关。材料与方法:使用Oncomine癌症微阵列数据库确定NCAM表达在不同类型人类癌症中的临床相关性。通过酶联免疫吸附试验(ELISA)评估了参与该研究的75例HCC患者的血清中sNCAM的表达。结果:根据OncomineCancer微阵列数据库分析,与正常组相比,NCAM在10种不同类型的癌症(如膀胱癌,脑癌和中枢神经系统癌)中被下调,而在肺癌,子宫肌平滑肌瘤和肉瘤中被上调。令人困惑的是,正常和肝癌组之间的NCAM表达没有明显差异。但是,我们通过定量ELISA发现,患有HE的HCC患者血清中的sNCAM水平(347.4±151.9 ng / ml)明显高于没有HE的HCC患者(260.3±104.2 ng / ml),p-值为0.008。 sNCAM可能是HCC患者HE的重要危险因素,秩相关分析相关系数为0.278(P <0.05)。结论:这项研究强调了肝癌患者血清sNCAM水平的上调与HE有关,并提示该高表达可作为一种指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号